FDA Approves Vraylar for Major Depressive Disorder
This is the fourth indication for Vraylar, a dopamine and serotonin partial agonist that can now be used as an adjunctive therapy in patients with major depressive disorder.
The FDA has approved AbbVie’s Vraylar (cariprazine), an oral antipsychotic approved to treat schizophrenia and bipolar depression, for an additional indication: as an adjunctive therapy to antidepressants to treat adults with major depressive disorder.
Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant, AbbVie said in a news release.
Major depressive disorder is one of the most common mental disorders in the United States. About one in five adults will experience this disorder during their lifetime.
The wholesale acquisition cost for a 30-day supply of Vraylar is $1,312.07 as of January 2022.
Gary Sachs, M.D.
“Patients with inadequate response to standard antidepressant medication are often frustrated by the experience of trying multiple medicines and still suffering from unresolved symptoms. Instead of starting over with another standard antidepressant, Vraylar works with an existing treatment and can help build on the progress already made,” said Gary Sachs, M.D., clinical vice president at Signant Health, associate clinical professor of psychiatry at Massachusetts General Hospital, and lead phase 3 clinical trial investigator.
Vraylar is co-developed by AbbVie and Gedeon Richter.
FDA’s approval is based on a phase 3 study showing a clinically and statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients treated with Vraylar at 1.5 mg a day plus an antidepressant therapy compared with placebo plus an antidepressant therapy.
A second registration-enabling study, RGH-MD-75, showed a clinically and statistically significant change from baseline to week eight in the MADRS total score for patients treated with Vraylar at 2 mg to 4.5 mg/day plus an antidepressant therapy compared with placebo plus an antidepressant therapy
Vraylar was generally well tolerated in six- and eight-week studies.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
